BACKGROUND: We estimated the 72-month efficacy of medical male circumcision (MMC) against herpes simplex virus 2 (HSV-2) incidence among men in the Kisumu MMC randomized trial. METHODS:From 2002 to 2005, 2784 men aged 18-24 were enrolled and randomized 1:1 to immediate circumcision or control. Cox proportional hazards regression incorporating stabilized inverse probability of treatment and censoring weights generated through marginal structural modeling was used to estimate the efficacy of MMC on HSV-2 risk. Conventional conditional Cox regression identified multivariable risks for HSV-2 seroconversion. RESULTS: Among 2044 HSV-2 seronegative men at baseline, the cumulative 72-month HSV-2 incidence was 33.5% (32.7% among circumcised men, 34.6% among uncircumcised men). In weight-adjusted Cox regression, the hazard ratio was 0.88 (95% confidence interval, .77-1.10). In multivariable analyses, risks for HSV-2 included human immunodeficiency virus (HIV) infection, genital ulcer disease (GUD), penile epithelial trauma, multiple recent sex partners, and being married /cohabiting. CONCLUSIONS:MMC had no effect on acquisition of HSV-2 during 72 months of follow-up. The temporal sequence and limited correlation between HSV-2, GUD, and penile epithelial trauma suggests that these are distinct phenomena rather than misclassification of HSV-2 symptoms. Determining the etiology of non-sexually transmitted infection GUD and penile epithelial trauma is needed, as both are commonly occurring risks for HSV-2 and HIV acquisition. CLINICAL TRIALS REGISTRATION: NCT0005937.
RCT Entities:
BACKGROUND: We estimated the 72-month efficacy of medical male circumcision (MMC) against herpes simplex virus 2 (HSV-2) incidence among men in the Kisumu MMC randomized trial. METHODS: From 2002 to 2005, 2784 men aged 18-24 were enrolled and randomized 1:1 to immediate circumcision or control. Cox proportional hazards regression incorporating stabilized inverse probability of treatment and censoring weights generated through marginal structural modeling was used to estimate the efficacy of MMC on HSV-2 risk. Conventional conditional Cox regression identified multivariable risks for HSV-2 seroconversion. RESULTS: Among 2044 HSV-2 seronegative men at baseline, the cumulative 72-month HSV-2 incidence was 33.5% (32.7% among circumcised men, 34.6% among uncircumcised men). In weight-adjusted Cox regression, the hazard ratio was 0.88 (95% confidence interval, .77-1.10). In multivariable analyses, risks for HSV-2 included human immunodeficiency virus (HIV) infection, genital ulcer disease (GUD), penile epithelial trauma, multiple recent sex partners, and being married /cohabiting. CONCLUSIONS: MMC had no effect on acquisition of HSV-2 during 72 months of follow-up. The temporal sequence and limited correlation between HSV-2, GUD, and penile epithelial trauma suggests that these are distinct phenomena rather than misclassification of HSV-2 symptoms. Determining the etiology of non-sexually transmitted infection GUD and penile epithelial trauma is needed, as both are commonly occurring risks for HSV-2 and HIV acquisition. CLINICAL TRIALS REGISTRATION: NCT0005937.
Authors: Supriya D Mehta; Stephen Moses; Kawango Agot; Elijah Odoyo-June; Hong Li; Ian Maclean; Donald Hedeker; Robert C Bailey Journal: AIDS Date: 2013-11-28 Impact factor: 4.177
Authors: Supriya D Mehta; Stephen Moses; Corette B Parker; Kawango Agot; Ian Maclean; Robert C Bailey Journal: AIDS Date: 2012-06-01 Impact factor: 4.177
Authors: Supriya D Mehta; John N Krieger; Kawango Agot; Stephen Moses; Jeckoniah O Ndinya-Achola; Corette Parker; Robert C Bailey Journal: J Urol Date: 2010-05-16 Impact factor: 7.450
Authors: Ron Gray; Godfrey Kigozi; Xiangrong Kong; Victor Ssempiija; Frederick Makumbi; Stephen Wattya; David Serwadda; Fred Nalugoda; Nelson K Sewenkambo; Maria J Wawer Journal: AIDS Date: 2012-03-13 Impact factor: 4.177
Authors: Steven J Reynolds; Fred Makumbi; Kevin Newell; Noah Kiwanuka; Paschal Ssebbowa; George Mondo; Iga Boaz; Maria J Wawer; Ronald H Gray; David Serwadda; Thomas C Quinn Journal: Lancet Infect Dis Date: 2012-03-19 Impact factor: 25.071
Authors: Supriya D Mehta; Stephen Moses; Corette B Parker; Kawango Agot; Ian Maclean; Robert C Bailey Journal: AIDS Date: 2013-01-02 Impact factor: 4.177
Authors: Aaron A R Tobian; Godfrey Kigozi; Maria J Wawer; David Serwadda; Thomas C Quinn; Ronald H Gray Journal: AIDS Date: 2013-01-02 Impact factor: 4.177
Authors: Reinhard Kaiser; Rebecca Bunnell; Allen Hightower; Andrea A Kim; Peter Cherutich; Mary Mwangi; Tom Oluoch; Sufia Dadabhai; Patrick Mureithi; Nelly Mugo; Jonathan Mermin Journal: PLoS One Date: 2011-03-15 Impact factor: 3.240
Authors: Supriya D Mehta; Stefan J Green; Ian Maclean; Hong Hu; Robert C Bailey; Patrick M Gillevet; Greg T Spear Journal: PLoS One Date: 2012-07-27 Impact factor: 3.240
Authors: Brian J Morris; Sean E Kennedy; Alex D Wodak; Adrian Mindel; David Golovsky; Leslie Schrieber; Eugenie R Lumbers; David J Handelsman; John B Ziegler Journal: World J Clin Pediatr Date: 2017-02-08
Authors: Robert C Bailey; Irene Nyaboke; Mary Ellen Mackesy-Amiti; Erick Okello; Valentine Pengo; Betha Ochomo; Mary Emmaculate Auma; Simon Were; Stella Ojuok; Evelyne Adoyo; Mildred Adhiambo; Marisa R Young; Rebeca M Plank; Fredrick O Otieno Journal: PLoS One Date: 2018-02-14 Impact factor: 3.240
Authors: Supriya D Mehta; Ashish K Pradhan; Stefan J Green; Ankur Naqib; Elijah Odoyo-June; Charlotte A Gaydos; Sheila Barry; Alan Landay; Robert C Bailey Journal: Sci Rep Date: 2017-11-13 Impact factor: 4.379
Authors: Katharine Jane Looker; Christine Johnston; Nicky J Welton; Charlotte James; Peter Vickerman; Katherine M E Turner; Marie-Claude Boily; Sami L Gottlieb Journal: BMJ Glob Health Date: 2020-03-08